Skip to main content

Table 2 ANOVA results for the effect of ACPA, treatment and time on changes in RA outcomes

From: ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial

 

Larsen

 

DAS28

 

HAQ

 

EuroQol

 

PCS

 

MCS

 

Effects

F

P

F

P

F

P

F

P

F

P

F

P

ACPA

31.90

<0.001

4.02

0.045

7.25

0.007

9.72

0.002

4.07

0.044

2.29

0.131

Time

16.83

<0.001

1.26

0.288

1.37

0.251

0.70

0.550

0.80

0.493

0.65

0.584

Treatment

9.93

<0.001

1.71

0.163

17.76

<0.001

11.47

<0.001

5.67

0.001

1.92

0.124

ACPA*Treatment

7.05

<0.001

3.99

0.008

0.48

0.696

2.94

0.032

3.22

0.022

1.84

0.138

  1. F = F-statistic; P = P-value; ACPA*Treatment = ACPA*Treatment interaction term. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RA, rheumatoid arthritis.